Global Rapid Covid-19 Antigen Test Kit Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027: Unexpected outbreak and spread of Covid-19 pandemic, rising investment and development of better and advanced rapid test, collaboration of government & private organizations and increasing funding by government are anticipated to drive the growth of Global Rapid Covid-19 Antigen Test Kit Market.
The rapid Covid-19 antigen test kit is a fast demonstrative test kit sensible for point-of-care testing that easily detects the presence or absence of an antigen in the patient’s body. It can help to reduce further transmission through early identification of positive cases, allowing a faster contact tracing. These kits are produced by the elements that fabricate in-vitro rapid symptomatic tests in the clinical equipment industry. Rapid Covid-19 antigen test kit normally gives results within a couple of hours. The organizations associated with manufacturing of these rapid test kits are mainly occupied with research, design and production of the rapid test kits. Furthermore, there are various benefits related with rapid Covid-19 antigen test kit like accuracy, low cost, quick result, early diseases diagnosis and stability at high temperature. Rapid Covid-19 antigen test kits are currently used in COVID-19 pandemic. Many significant biotechnology and pharmaceutical organizations have built up their own rapid Covid-19 antigen test kits, and many are as yet contributing, researching and working on the improvement of better and advanced rapid test kits. Rapid Covid-19 antigen test kits are utilized in emergency clinics and centers, home consideration, diagnostic labs, and research foundations.
Covid-19 pandemic has shown a positive impact on growth of global rapid Covid-19 antigen test kit market. During Covid-19 pandemic, requirement of rapid Covid-19 antigen test kits has shown tremendously increase due to the rising number of covid-19 cases worldwide. Additionally, the outbreak of Covid-19 has set out a vital opportunity for manufacturers to increase rapid diagnostic test kit supplies to contain the spread of Covid-19 disease. Also, numbers of government and private organizations are invested in the development of kit Covid-19 kit for the treatment of Covid-19 patients. For instance, Cipla and the Premier Medical Corporation Private Limited announced partnership for the quick antigen test of Covid-19 commercialization in Indian 2020. However, due to the lockdown procedures, the supply-chain is still disturbed and made it troublesome for players to predict the industries regaining. For example, Currently, India is in the second wave of Covid-19 and reporting over 300,000 daily coronavirus infections. Thus, the Indian government announced the lockdown to the reduced risks of Covid-19 infection.
Global rapid Covid-19 antigen test kit market is segmented on the basis of technology, end-users and region & country level. Based upon technology, global rapid covid-19 antigen test kit market is classified into chromatographic immunoassay, fluorescent immunoassay and others. Based upon end-user, the market is divided into hospitals & clinics, diagnostic center, home care and others.
By Technology:
By End-User:
The regions covered in this global rapid Covid-19 antigen test kit market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of rapid Covid-19 antigen test kit is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Some major key players for global Rapid Covid-19 Antigen Test Kit market report cover prominent players are Abbott Rapid Diagnostics, Cipla, AMEDA Labordiagnostik GmbH, Becton Dickinson, Beijing Lepu Medical Technology, BIOSYNEX SWISS SA, CerTest Biotect S.L., Hangzhou Clongene Biotech, Healgen Scientific Limited, LumiraDX UK Ltd., nal von minden GmbH, Quidel Corporation, SD BIOSENSOR, Inc.; Roche, Siemens Healthineers, Xiamen Boson Biotech Co, Zhejiang Orient Gene Biotech Co.,Ltd and others.
News: Cipla Launched Rapid Antigen Test for Covid-19 Diagnosis
December 16th, 2020; Cipla launched the quick antigen test kits for Covid-19 diagnosis with the association of Premier Medical Corporation Private Limited in India. The test is a quick mark of-care nasopharyngeal swab test that simply recognized the presence or absence of Covid-19 antigen in the patient's body, producing results inside 15-20 minutes. The test is marketed under the brand name 'CIPtest'. This is Cipla's second dispatch in the diagnostics space after Elifast ELISA Test Kit. In this joint effort, Cipla will further liable for the marketing and distribution of the rapid antigen detection test for the subjective identification of SARS-CoV-2 antigen that made by Premier Medical Corporation Private Limited.
One of the major factors driving the growth of global Rapid Covid-19 Antigen Test Kit market is sudden outbreak and spread of Covid-19 virus around the world. According to World Health Organization (WHO), globally, the highest percentage of cases had been reported in the 25-39 age groups, with approximately 50% of cases in the 25-64 age groups. Also, the percentage of deaths increases with age, and approximately 75% of deaths were in those aged 65 years and above in 2020. In addition, rising investment and development of better and superior Rapid Covid-19 Antigen Test Kit is also empowering the growth of Rapid Covid-19 Antigen Test Kit market in forecast period. For instance; the Foundation for Innovative New Diagnostics (FIND) and Unitaid announced that the first contracts had been finalized, following an open call for Expressions of Interest (EOI) that launched on July 4th, 2020 to drive reasonable access to fit-for-purpose antigen-detecting rapid diagnostic tests (Ag RDTs) for Covid-19. Furthermore, association of government & private organizations and increasing funding by government also fostering the market growth. For instance; in 2020, The Pan American Health Organization organized 190,000 new COVID-19 antigen diagnostic tests which offered to four countries in Latin America and the Caribbean and took training to implement pilot testing of their operation. Also, PAHO’s strategic fund, a regional technical cooperation mechanism for pooled procurement of essential medicines and health supplies, worked with the countries to facilitate access to these diagnostic tests. For example; the Government of Canada announced the first-ever contribution to the therapeutics mainstay of UNICEF's that recently launched Access to COVID-19 Tools Accelerator Supplies Financing Facility (""ACT-A SFF"") to fight the pandemic.
However, Rapid Covid-19 Antigen Test Kit may need confirmatory testing because it may give false test result and less sensitive as compared to Nucleic Acid Amplification Tests (NAATs) especially among asymptomatic people which may hamper the market growth. In spite of that, growing investments by government and private organizations for production of Rapid Covid-19 Antigen Test Kit around the world can offer more opportunities for the further growth of the market.
North America is dominating the Rapid Covid-19 Antigen Test Kit market with the highest rate due to growing investments in research developments of rapid Covid-19 antigen test kit, presence of key players and merger of various companies & government for development of antigen tests in this region. For instance, recently, Kroger Health reported that it offered a Smartphone empowered, at-home rapid COVID-19 antigen test kit to patients across the country. Also, Kroger Health has aims to make the at-home fast antigen test across the U.S. According to a published news on December 2nd, 2020, Surgisphere developed an intelligent tool that used three common laboratory tests to identify patients with coronavirus infection. The company announced the availability of a rapid diagnostic tool for novel coronavirus that leveraged the power of its global research network and advanced machine learning in the medical industry. Moreover, key industry members are continually speeding up the supply and formation of rapid tests to address the growing requirement for the powerful regulation of the COVID-19 pandemic.
Europe is projected to capture the significant revenue share in the global rapid Covid-19 antigen test kit market due to growing cases Covid-19 patients and increasing research and development activities to develop more effective antigen test. For example, recently, Queensland company AnteoTech announced that its rapid COVID-19 test kit ready to boomed European markets. According to News on April 29, 2021, Anteotech invested USD 12M for launching Eugeni rapid COVID-19 antigen test kit in Europe. Its EuGeni Covid-19 antigen rapid test kit is for single-use, disposable immune chromatographic rapid test intended to be used by healthcare professionals.
Asia Pacific is the fastest developing region in the global Rapid Covid-19 Antigen test kit market during the forecast period due to the growing need for the test owing to the increasing prevalence of Covid-19 cases in this region. According to World Health Organization (WHO), about 20,282,833 cases and 230,138 deaths reported in India up to April 2021. In addition, growing number of collaborations between government and private organizations in the region. For instance; in May 2020, the Indian government partnered with ZydusCadila, a Gujarat-based drug organization for large scale manufacturing of Elisa kits to detect Covid-19 infection, which were produced by the Indian Council of Medical Research. The Indian Council of Medical Research (ICMR) has approved its agreement to Trivitron Healthcare Private Limited, a medical technology company to commercially launch their flagship product Covid-19 rapid testing antigen kit. This Covid-19 antigen kits will be branded as ‘Biocard Pro Covid-19 Antigen Kits’ and gives result in 7-10 minutes.
Report Analysis | Details |
---|---|
Historical data | 2015 - 2020 |
Forecast Period | 2021 - 2027 |
Market Size in 2020: | XX.xx |
Base year considered | 2020 |
Forecast Period CAGR %: |
XX.xx % |
Market Size Expected in 2027: | XX.xx |
Tables, Charts & Figures: | 175 |
Pages | 200 |
Key Players/Companies | Abbott Rapid Diagnostics, Cipla, AMEDA Labordiagnostik GmbH, Becton Dickinson, Beijing Lepu Medical Technology, BIOSYNEX SWISS SA, CerTest Biotect S.L., Hangzhou Clongene Biotech, Healgen Scientific Limited, LumiraDX UK Ltd., nal von minden GmbH, Quidel Corporation, SD BIOSENSOR, Inc.; Roche, Siemens Healthineers, Xiamen Boson Biotech Co, Zhejiang Orient Gene Biotech Co.,Ltd and others |
Segments Covered | By Technology, By End-User |
Regional Analysis | North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa |
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
+44-1173181773
sales@brandessenceresearch.com
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com
JOIN USFIND ASSISTANCE
LONDON OFFICE
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
FOLLOW US
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®